XR5944

Known as: XR 5944 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2014
012320012014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can… (More)
Is this relevant?
2011
2011
DNA-intercalating molecules can impair DNA replication, DNA repair, and gene transcription. We previously demonstrated that… (More)
Is this relevant?
2008
2008
Previous in vitro cleavage data showed that XR11576 and XR5944 stabilised topoisomerase I and topoisomerase II complexes on DNA… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2007
2007
The anticancer drug XR5944 was originally developed as a topoisomerase inhibitor and was subsequently shown to be a transcription… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
The substituted phenazines XR11576 and XR5944 were originally described as dual topoisomerase-I/II poisons. Subsequent reports… (More)
Is this relevant?
2005
2005
XR5944 (MLN944), a novel bis-phenazine, has demonstrated potent cytotoxic activity against a variety of murine and human tumour… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity… (More)
Is this relevant?
2004
2004
XR5944 (MLN944) is a novel DNA targeting agent with potent antitumor activity, both in vitro and in vivo, against several murine… (More)
Is this relevant?
2004
2004
2100 Background: XR5994 (MLN944) is a novel DNA/RNA targeting agent with a mechanism of action distinct from that of currently… (More)
Is this relevant?
2001
2001
Inhibitors of topoisomerases are widely used in the treatment of cancer, including inhibitors of topoisomerase I (camptothecin… (More)
Is this relevant?